High-dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carcinoma : a Retrospective Analysis of Response and Survival in Patients Treated in the Surgery Branch at the National Cancer Institute Between 1986 and 2006

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2008 May 7

PMID 18457330

Citations 198

Authors

Jacob A Klapper

Stephanie G Downey

Franz O Smith

James C Yang

Marybeth S Hughes

Udai S Kammula

Richard M Sherry

Richard E Royal

Seth M Steinberg

Steven Rosenberg

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients. The current study presents the authors' 20-year experience administering this immunotherapeutic agent.

Methods: Patients with metastatic RCC (n = 259) were treated with HD IL-2 alone from January 13, 1986 through December 31, 2006 at the Surgery Branch of the National Cancer Institute. Potential predictive factors for response and survival, both pretreatment and treatment-related, were first subjected to univariate analysis and then to multivariate logistic regression or a Cox proportional hazards model. Finally, the authors investigated Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic factors for survival to assess their predictive value in the patient population in the current study.

Results: A total of 23 patients experienced a complete response and 30 patients achieved a partial response, for an overall objective response rate of 20%. All partial responders had developed disease recurrence at the time of last follow-up, but only 4 complete responders had experienced disease recurrence by that time. Despite toxicities, only 2 patients developed treatment-related mortalities over this same time period. A higher baseline weight (P = .05) and MSKCC prognostic factors (P = .02) were found to be the variables most associated with response. For survival >4 years and overall survival, several pretreatment and treatment-related factors maintained significance, but none more so than response (P < .0001).

Conclusions: HD IL-2 can induce complete tumor regression in a small number of patients, and many patients have experienced extended disease-free intervals. Given its relative safety, HD IL-2 should still be considered a first-line therapy in patients with metastatic RCC who have an overall good performance status.

Citing Articles

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.

Barisic S, Brahmbhatt E, Cherkasova E, Spear T, Savani U, Pierre S J Immunother Cancer. 2024; 12(9).

PMID: 39266213 PMC: 11409391. DOI: 10.1136/jitc-2024-009147.

Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.

Prodi E, Neri D, De Luca R Onco Targets Ther. 2024; 17:697-715.

PMID: 39224695 PMC: 11368152. DOI: 10.2147/OTT.S480787.

Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.

Boersma B, Poinot H, Pommier A Pharmaceutics. 2024; 16(8).

PMID: 39204319 PMC: 11357675. DOI: 10.3390/pharmaceutics16080974.

IL-2 based cancer immunotherapies: an evolving paradigm.

Rokade S, Damani A, Oft M, Emmerich J Front Immunol. 2024; 15:1433989.

PMID: 39114660 PMC: 11303236. DOI: 10.3389/fimmu.2024.1433989.

References

Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A . Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005; 11(10):3714-21. DOI: 10.1158/1078-0432.CCR-04-2019. View

Sleijfer D, Janssen R, Buter J, De Vries E, Willemse P, Mulder N . Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992; 10(7):1119-23. DOI: 10.1200/JCO.1992.10.7.1119. View

Bui M, Seligson D, Han K, Pantuck A, Dorey F, Huang Y . Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9(2):802-11. View

Fyfe G, Fisher R, Rosenberg S, Sznol M, Parkinson D, Louie A . Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13(3):688-96. DOI: 10.1200/JCO.1995.13.3.688. View

Upton M, Parker R, Youmans A, Mcdermott D, Atkins M . Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005; 28(5):488-95. DOI: 10.1097/01.cji.0000170357.14962.9b. View

Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

Rosenberg S, Yang J, White D, Steinberg S . Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998; 228(3):307-19. PMC: 1191483. DOI: 10.1097/00000658-199809000-00004. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

Yang J, Topalian S, Schwartzentruber D, Parkinson D, Marincola F, Weber J . The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with.... Cancer. 1995; 76(4):687-94. DOI: 10.1002/1097-0142(19950815)76:4<687::aid-cncr2820760424>3.0.co;2-m. View

10.

Rosenberg S, Lotze M, Yang J, Linehan W, Seipp C, Calabro S . Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989; 7(12):1863-74. DOI: 10.1200/JCO.1989.7.12.1863. View

11.

Rosenberg S, Lotze M, Yang J, Topalian S, Chang A, Schwartzentruber D . Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993; 85(8):622-32. DOI: 10.1093/jnci/85.8.622. View

12.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

13.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838. View

14.

Yang J, Sherry R, Steinberg S, Topalian S, Schwartzentruber D, Hwu P . Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21(16):3127-32. PMC: 2275327. DOI: 10.1200/JCO.2003.02.122. View

15.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34. DOI: 10.1056/NEJMoa060655. View

16.

Atkins M, Sparano J, Fisher R, Weiss G, Margolin K, Fink K . Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993; 11(4):661-70. DOI: 10.1200/JCO.1993.11.4.661. View

17.

Rosenberg S, Lotze M, Yang J, Aebersold P, Linehan W, Seipp C . Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989; 210(4):474-84; discussion 484-5. PMC: 1357927. DOI: 10.1097/00000658-198910000-00008. View

18.

Vogelzang N, Lipton A, Figlin R . Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol. 1993; 11(9):1809-16. DOI: 10.1200/JCO.1993.11.9.1809. View

19.

Royal R, Steinberg S, Krouse R, Heywood G, White D, Hwu P . Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am. 1996; 2(2):91-8. View

20.

Palmer P, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H . Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992; 3(6):475-80. DOI: 10.1093/oxfordjournals.annonc.a058239. View